Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 20/20 | 0.56 |
| ▸ | TTK | P33981 | 5/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26159808 | 1.00 | PRKDC (0.56) | PRKDCTTKCSF1RKCNH2AURKA | |
| SCHEMBL26159815 | 1.00 | PRKDC (0.56) | PRKDCTTKCSF1RKCNH2AURKA | |
| SCHEMBL23948604 | 0.96 | PRKDC (0.53) | PRKDCTTKCSF1RKCNH2AURKA | |
| SCHEMBL23948560 | 0.96 | PRKDC (0.53) | PRKDCTTKCSF1RKCNH2AURKA | |
| SCHEMBL23948133 | 0.94 | PRKDC (0.60) | PRKDCTTKCSF1RKCNH2 | |
| SCHEMBL23948157 | 0.93 | PRKDC (0.55) | PRKDCTTKCSF1RKCNH2AURKA | |
| SCHEMBL23948529 | 0.92 | PRKDC (0.66) | PRKDCTTKCSF1RKCNH2 | |
| SCHEMBL23948199 | 0.91 | PRKDC (0.54) | PRKDCTTKCSF1RKCNH2 | |
| SCHEMBL23948583 | 0.91 | PRKDC (0.54) | PRKDCTTKCSF1RKCNH2 | |
| SCHEMBL29502057 | 0.91 | PRKDC (0.54) | PRKDCTTKCSF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | PRKDC 316/4885TTK 1365/4885CSF1R 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.